Price Tag of Guidant Is Lowered
Johnson & Johnson will pay $4 billion less than originally agreed to acquire Guidant, troubled maker of implantable heart devices, under revised $21.5 billion deal; new agreement is apparent acknowledgment by Guidant of how significantly its outlook has declined because of disclosures about product problems, device recalls, investigations and lawsuits; move clears way for Johnson & Johnson to become major player in market for defibrillators and pacemakers, lucrative product area it has long sought to enter (M)